Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-303 first-line tarlatamab combination study in extensive-stage small cell lung cancer
NL-OMON60582Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Primary endpoint: Primary endpoint(s). Started Dec 2022; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON60582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60582.